|Print View Attached Docs:|
|Alias Names:||Human Epidermal growth factor Receptor 2 / ErbB-2 / c-erbB-2 / EGF receptor 2 / breast cancer / HER2 / HER / HER 2 / HER2|
|Methodology:||Enzyme-Linked Immunosorbent Assay (ELISA)|
|Released:||1-8 days after setup at PeaceHealth Laboratories’ reference lab.|
|Specimen Collection Details|
|Collection:||One 7.5 mL serum separtor tube (SST).|
|Handling:||Allow to clot, centrifuge and separate serum from cells and pour into a plastic vial. Freeze.|
|Stability:||4 days ambient, 3 weeks refrigerated, or 1 year frozen.|
|Standard Volume:||1 mL serum.|
|Minimum Volume:||300 µL serum.|
|Comments:||This assay is performed using the Siemens Medical Solutions Diagnostics HER-2/neu Microtiter ELISA. Results obtained with different assay methods or kits cannot be used interchangeably.
Serum HER-2/neu levels may not always indicate the presence or absence of malignant disease. The HER-2/neu value should be used as part of an overall clinical assessment that includes additional clinical evaluation and diagnostic tests. In metastatic breast cancer cases, 92% of patients having serum HER-2/neu of 37 µg/L or greater are tissue HER-2 positive, whereas only 27% of patients having values less than 37 µg/L are tissue HER-2 positive.